These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38882681)

  • 1. Isomer-sourced structure iteration methods for
    Hu Z; Martí J
    Comput Struct Biotechnol J; 2024 Dec; 23():2418-2428. PubMed ID: 38882681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
    Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
    Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of NRAS Q61K with a ligand-induced pocket near switch II.
    Gebregiworgis T; Chan JY; Kuntz DA; Privé GG; Marshall CB; Ikura M
    Eur J Cell Biol; 2024 Jun; 103(2):151414. PubMed ID: 38640594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.
    Posch C; Sanlorenzo M; Vujic I; Oses-Prieto JA; Cholewa BD; Kim ST; Ma J; Lai K; Zekhtser M; Esteve-Puig R; Green G; Chand S; Burlingame AL; Panzer-Grümayer R; Rappersberger K; Ortiz-Urda S
    J Invest Dermatol; 2016 Oct; 136(10):2041-2048. PubMed ID: 27251789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAF
    Jandova J; Wondrak GT
    J Invest Dermatol; 2022 May; 142(5):1456-1465.e1. PubMed ID: 34687745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
    Kumar R; Njauw CN; Reddy BY; Ji Z; Rajadurai A; Klebanov N; Tsao H
    Oncogene; 2019 May; 38(18):3504-3520. PubMed ID: 30651601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and detection of actionable BRAF V600 and NRAS Q61 mutations in malignant peripheral nerve sheath tumor by droplet digital PCR.
    Kao EY; Wakeman KM; Wu Y; Gross JM; Chen EY; Ricciotti RW; Liu YJ; Mantilla JG
    Hum Pathol; 2022 Nov; 129():90-97. PubMed ID: 36067829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
    Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M
    Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering Conformational Changes of the GDP-Bound NRAS Induced by Mutations G13D, Q61R, and C118S through Gaussian Accelerated Molecular Dynamic Simulations.
    Yu Z; Su H; Chen J; Hu G
    Molecules; 2022 Aug; 27(17):. PubMed ID: 36080363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SP174, NRAS Q61R Mutant-Specific Antibody, Cross-Reacts With KRAS Q61R Mutant Protein in Colorectal Carcinoma.
    Lasota J; Kowalik A; Felisiak-Golabek A; Inaguma S; Wang ZF; Pięciak L; Zięba S; Pęksa R; Kopczynski J; Okoń K; Waloszczyk P; Gozdz S; Biernat W; Miettinen M
    Arch Pathol Lab Med; 2017 Apr; 141(4):564-568. PubMed ID: 28353383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma.
    Ilie M; Long-Mira E; Funck-Brentano E; Lassalle S; Butori C; Lespinet-Fabre V; Bordone O; Gay A; Zahaf K; Poissonnet G; Lacour JP; Bahadoran P; Ballotti R; Gros A; Dutriaux C; Saiag P; Merlio JP; Vergier B; Emile JF; Hofman V; Hofman P
    J Am Acad Dermatol; 2015 May; 72(5):786-93. PubMed ID: 25659223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced BRAF engagement by NRAS mutants capable of promoting melanoma initiation.
    Murphy BM; Terrell EM; Chirasani VR; Weiss TJ; Lew RE; Holderbaum AM; Dhakal A; Posada V; Fort M; Bodnar MS; Carey LM; Chen M; Burd CJ; Coppola V; Morrison DK; Campbell SL; Burd CE
    Nat Commun; 2022 Jun; 13(1):3153. PubMed ID: 35672316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro.
    Eskandarpour M; Huang F; Reeves KA; Clark E; Hansson J
    Int J Cancer; 2009 Jan; 124(1):16-26. PubMed ID: 18814281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NRAS
    Boscolo E; Pastura P; Schrenk S; Goines J; Kang R; Pillis D; Malik P; Le Cras TD
    Angiogenesis; 2022 Aug; 25(3):331-342. PubMed ID: 35391614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
    Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
    Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mutation panel comprising BRAF
    Eng ZH; Ahmad Jefry MM; Ng KL; Abdul Aziz A; Mat Junit S
    Malays J Pathol; 2023 Dec; 45(3):375-390. PubMed ID: 38155379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.
    Petti C; Molla A; Vegetti C; Ferrone S; Anichini A; Sensi M
    Cancer Res; 2006 Jul; 66(13):6503-11. PubMed ID: 16818621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
    Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
    J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.